SOURCE: GenSpera

GenSpera

June 09, 2015 08:30 ET

KTLA TV's Health Smart Showcases GenSpera's Cancer Research

SAN ANTONIO, TX and LOS ANGELES, CA--(Marketwired - Jun 9, 2015) - GenSpera, Inc. (OTCQB: GNSZ) announced today Craig A. Dionne, Ph.D., chairman and chief executive officer at GenSpera, was interviewed by Angel Kim of KTLA-TV.

Los Angeles's award winning KTLA TV, which serves Los Angeles and Southern California, invited Dr. Dionne to educate their viewers on a special Health Smart segment, during which Dr. Dionne answered questions and presented the latest clinical challenges facing those diagnosed with cancer. The segment will air at 10:00 pm Pacific Standard Time during the evening news on June 9, 2015.

Dr. Dionne stated, "It is unfortunate that everyone in the United States has a loved one or knows someone who is currently being treated or has succumbed to cancer. Health Smart is a great forum to help educate the public on cancer research and the potential benefit of our drug mispagargin. Mispagargin is currently being investigated in clinical trials for glioblastoma (brain cancer) and hepatocellular carcinoma-HCC (liver cancer)."

About Mispagargin
Mipsagargin is a prodrug in human clinical trials for several different tumor types. Mipsagargin consists of a thapsigargin derivative, 12ADT, coupled to a peptide that helps solubilize the prodrug and prevents its internalization into cells until the peptide is removed. The mechanism of action works by targeting the enzyme PSMA, which is highly expressed on the surface of almost all cancer tumor vasculature, including those of glioblastoma. PSMA recognizes and removes the peptide, releasing the active ingredient 12ADT into the cell and bringing about cell death. The prodrug delivery system ensures that mipsagargin is activated only within the tumor, providing greater anti-tumor efficacy and minimizing side effects. 

About GenSpera
GenSpera, Inc. is a San Antonio-based biotech company that unlocks conventional thinking to conceive, design, and develop cancer therapies. GenSpera's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a patented prodrug delivery system that provides for targeted release of drug candidates within tumors. GenSpera's lead drug candidate, mipsagargin, was granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA) in 2013 for evaluation in patients with hepatocellular carcinoma (liver cancer).

For additional information on GenSpera, visit www.genspera.com and connect on Twitter, LinkedIn, Facebook, YouTube and Google+.

Cautionary Statement Regarding Forward Looking Information
This communication may contain forward-looking statements. Investors are cautioned that statements in this document regarding potential applications of GenSpera's technologies or the future prospects of the company constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights and the acceptance of GenSpera's proposed therapies by the health community. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties will be detailed from time to time in GenSpera's periodic reports filed with the Securities and Exchange Commission.

Contact Information